Pamidronic acid
| Clinical data | |
|---|---|
| Trade names | Aredia, Pamimed, among others | 
| Other names | Pamidronate disodium pentahydrate, pamidronate disodium | 
| AHFS/Drugs.com | International Drug Names | 
| MedlinePlus | a601163 | 
| Pregnancy category | 
 | 
| Routes of administration | Intravenous | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | n/a | 
| Protein binding | 54% | 
| Metabolism | Nil | 
| Elimination half-life | 28 ± 7 hours | 
| Excretion | Renal | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.049.897 | 
| Chemical and physical data | |
| Formula | C3H11NO7P2 | 
| Molar mass | 235.069 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.
It was patented in 1971 and approved for medical use in 1987.